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Abstract
Background: To assess the performance of Candida albicans germ tube antibody (CAGTA), (1→ 3)-ß-D-glucan
(BDG), mannan antigen (mannan-Ag), anti-mannan antibodies (mannan-Ab), and Candida DNA for diagnosing
invasive candidiasis (IC) in ICU patients with severe abdominal conditions (SAC).
Methods: A prospective study of 233 non-neutropenic patients with SAC on ICU admission and expected
stay ≥ 7 days. CAGTA (cutoff positivity ≥ 1/160), BDG (≥80, 100 and 200 pg/mL), mannan-Ag (≥60 pg/mL),
mannan-Ab (≥10 UA/mL) were measured twice a week, and Candida DNA only in patients treated with
systemic antifungals. IC diagnosis required positivities of two biomarkers in a single sample or positivities of
any biomarker in two consecutive samples. Patients were classified as neither colonized nor infected (n = 48),
Candida spp. colonization (n = 154) (low-grade, n = 130; high-grade, n = 24), and IC (n = 31) (intra-abdominal
candidiasis, n = 20; candidemia, n = 11).
Results: The combination of CAGTA and BDG positivities in a single sample or at least one of the two
biomarkers positive in two consecutive samples showed 90.3 % (95 % CI 74.2–98.0) sensitivity, 42.1 % (95 % CI
35.2–98.8) specificity, and 96.6 % (95 % CI 90.5–98.8) negative predictive value. BDG positivities in two consecutive
samples had 76.7 % (95 % CI 57.7–90.1) sensitivity and 57.2 % (95 % CI 49.9–64.3) specificity. Mannan-Ag, mannan-Ab,
and Candida DNA individually or combined showed a low discriminating capacity.
Conclusions: Positive Candida albicans germ tube antibody and (1→ 3)-ß-D-glucan in a single blood sample
or (1→ 3)-ß-D-glucan positivity in two consecutive blood samples allowed discriminating invasive candidiasis
from Candida spp. colonization in critically ill patients with severe abdominal conditions. These findings may
be helpful to tailor empirical antifungal therapy in this patient population.
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Background
Accurate and timely diagnosis of invasive candidiasis
(IC) from the patient’s perspective and to optimize anti-
fungal therapy in the intensive care unit (ICU) setting
remains a topic of great interest [1–6]. The use of single
or combined biomarkers, such as (1→ 3)-ß-D-glucan
(BDG), Candida albicans germ tube antibody (CAGTA),
mannan antigen (mannan-Ag), anti-mannan antibodies
(mannan-Ab), and polymerase chain reaction (PCR)
detection of Candida DNA has received increasing at-
tention [7–10], but the appropriate incorporation into
clinical practice remains controversial. We investigated
the performance of these five tests, alone and in combin-
ation, for discriminating IC in critically ill patients with
severe abdominal conditions (SAC).
Methods
Design and study population
Between November 1, 2012 and February 28, 2014, all
consecutive adult non-neutropenic patients with SAC on
ICU admission and an expected stay of ≥ 7 days were in-
cluded in a prospective, cohort, observational, and mul-
ticenter study. The study protocol was approved by the
Ethics Committee of Hospital Universitario de Valme
(Sevilla, Spain) and the Spanish Agency for Medicines
and Health Care Products (AEMPS). The codes and
dates of approval of the study protocol were CEIC-A1,
ref. 350/12 (May 29, 2012) for the Ethics Committee of
Hospital de Valme, and September 14, 2012 for AEMPS.
Informed consent was obtained from the patients or
their legal representatives.
A severe abdominal condition (SAC) was defined as
the process that caused gastrointestinal dysfunction or
failure in the context of a medical abdominal disease
(e.g., severe acute pancreatitis) or an abdominal surgical
condition requiring elective or urgent procedures, with
related complications (e.g., gastrointestinal perforation,
hepatobiliary and pancreatic disorders, peritonitis, intra-
abdominal abscess, anastomotic leak, etc.) and pro-
longed postoperative stay after complicated abdominal
surgery. Therefore, the definition of SAC included med-
ical and surgical patients. Data for each patient was
recorded using an electronic case report form.
Besides neutropenia defined as total leukocyte count <
1000/mm3, other exclusion criteria on ICU admission
were as follows: age below 18 years, human immunodefi-
ciency virus (HIV) infection, active malignancy, current
immunosuppression or immunosuppressive therapy, treat-
ment with immunomodulating agents (monoclonal anti-
bodies) in the previous 3 months, use of a dose of ≥
20 mg/day of prednisone or its equivalent within 1 month
prior to ICU admission, spontaneous bacterial peritonitis
in liver cirrhosis or advanced chronic liver disease, solid
organ or bone marrow transplant recipients, chronic
inflammatory bowel disease (ulcerative colitis, Crohn’s dis-
ease), life expectancy less than 1 week, Acute Physiology
and Chronic Health Evaluation (APACHE II) score > 35
on ICU admission, documented Candida spp. infection
during the week prior to ICU admission, treatment with
antifungal agents before ICU admission or before inclu-
sion in the study, limitation of the therapeutic effort, re-
fusal to sign the informed consent, and inadequate data
collection (incompleteness of the protocol specifications).
Screening, microbiological cultures, and Candida score
Surveillance cultures for the screening Candida spp.
were performed twice a week from the fourth day of
ICU admission. Surveillance samples were obtained from
feces or rectal swabs, urine, tracheal aspirates (or
protected specimen brush or bronchoalveolar lavage),
oropharyngeal swabs (in patients without mechanical
ventilation), peripheral blood, vascular lines, wound/
drainage exudates, or infected foci at the discretion of
the attending physician. Samples were seeded directly
into Candida CHROMagar™ Chromogen culture medium
(Hardy Diagnostics, Santa Maria, CA, USA). All catheter
tips removed were cultured in blood agar and Sabouraud
agar by the Maki roll plate technique. Blood cultures were
processed using the automated BACTEC™ system (Becton
Dickinson Diagnostic Instrument System, Paramus, NJ,
USA) or other standardized methods. Results were con-
sidered positive in the presence of Candida growth in the
culture medium. Identification at the species level was
required. Candida score [11, 12] was calculated coinciding
with collection of samples and once culture data were
available.
Serological biomarkers
Blood samples (15 mL) were collected in three tubes
without anticoagulant, centrifuged at 1800 rpm for
10 min, separated into aliquots, and stored at –80 °C
until analysis. None underwent more than one freeze–
thaw cycle, and serum and reagents were tempered and
homogenized before processing.
The BDG assay (Fungitell™, Associates of Cape Cod,
Inc., East Falmouth, MA, USA) was performed accord-
ing to the manufacturer’s recommendations: under lam-
inar flow hood, duplicated and saving the mean value of
both measurements and repeating the assay when be-
tween both BDG values there existed at least a 20 % dif-
ference. Also, when the BDG values were greater than
500 pg/mL, samples were diluted and retested. The cut-
off value was ≥ 80 pg/mL. CAGTA detection was per-
formed by an immunofluorescence test (Vircell kit assay,
Granada, Spain) according to the manufacturer’s instruc-
tions. The cutoff value for positive CAGTA was ≥ 1/160.
For mannan-Ag and mannan-Ab, Platelia Candida Ag
Plus and Platelia Candida Ab Plus were used in the
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automated EVOLISTM Twin Plus device (Bio-Rad,
Marnes-la-Coquette, France). The cutoff values for
positive mannan-Ag and mannan-Ab were ≥ 60 pg/mL
and ≥ 10 AU/mL, respectively. None of the tests were
performed in real time and, therefore, were not avail-
able to clinician’s decision making.
Multiplex quantitative real-time PCR (MRT-PCR)
The MRT-PCR assay [13] was performed to detect the
six most frequent species of the genus Candida in inva-
sive candidiasis (IC). The technique detected C. albicans,
C. parapsilosis, C. tropicalis, C. glabrata, C. krusei, and
C. guilliermondii using specific molecular beacon probes
labeled with different fluorescent dyes: FAM, HEX, ROX
and CYAN 500. Primers and probes were designed on
the basis of the nucleotide sequences of the ITS riboso-
mal DNA region from strains belonging to the collection
of the Spanish National Center of Microbiology. The
probes targeted the ITS1 or ITS2 regions of ribosomal
DNA. These regions were chosen as targets because of
the possibility of designing a suitable probe for each
case. Beacon Designer 5.0 software (Premier Biosoft,
Palo Alto, CA, USA) was used to design primers and
probes. The assay consisted of two multiplex PCRs: reac-
tion one (C. albicans, C. parapsilosis, and C. tropicalis),
which was performed using the LightCycler Probes
Master Kit (Roche Diagnostics, Madrid, Spain); and re-
action two (C. glabrata, C. krusei, and C. guilliermondii),
which was performed using the 2x Sensimix Probe Kit
(Quantace, Ecogen, Madrid, Spain). Both PCRs were
performed simultaneously in the LightCycler 480 System
(Roche Diagnostics, Mannheim, Germany). DNA from
blood and sera was extracted using the QIAamp DNA
Mini Kit (Qiagen Izasa, Madrid, Spain). Elution was per-
formed with 50 mL of buffer; the PCR was performed
with 2 mL of DNA extracted from each sample. All sam-
ples were performed in duplicate and quantification
standards were run in conjunction with each set of sam-
ples and negative controls.
Study protocol and collection of data
The following variables were recorded: age, sex, reason
for ICU admission, APACHE II score, Sepsis-related
Organ Failure Assessment (SOFA) score on ICU admis-
sion, comorbidities, and risk factors associated with
Candida spp. colonization or infection. According to
diagnosis at the time of ICU admission, patients were
classified as medical or surgical. Surgical patients were
those for whom the reason of ICU admission was the
postoperative control of an elective or urgent surgical
procedure. All surgical procedures and the number of
operations performed in each patient were recorded.
Medical patients undergoing major surgery during ICU
admission were considered surgical patients.
Underlying diseases included diabetes mellitus treated
with oral hypoglycemic agents and insulin-dependent
diabetes, chronic obstructive pulmonary disease (COPD)
(airflow limitation defined as forced expiratory volume
during the first second (FEV1)/forced vital capacity
(FVC) < 88 % predicted in men and < 89 % predicted in
women, or a postbronchodilator ratio of FEV1/FVC < 0.7),
chronic liver disease (confirmed by liver biopsy or the
presence of signs of portal hypertension, such as esopha-
geal varices or ascites), chronic renal failure (in patients
requiring hemodialysis or peritoneal dialysis), severe heart
failure (defined as grades III and IV according to the New
York Heart Association [NYHA] classification, alcoholism
(defined as ethanol ingestion > 80 g/day), and HIV infec-
tion with adequate clinical control.
Risk factors for the development of Candida spp.
colonization or infection included the following: central
venous catheters, arterial catheters, total parenteral
nutrition, mechanical ventilation, continuous renal re-
placement therapy (hemofiltration), treatment with
corticosteroids (defined as intravenous administration
of steroids for 5 days or more), and broad-spectrum
antimicrobial treatment.
Once the patient was included in the study, the follow-
ing data were recorded twice a week from the fourth day
of ICU stay and for 3 weeks: surveillance cultures, Acute
Physiology and Chronic Health Evaluation (APACHE II)
score, Sepsis-related Organ Failure Assessment (SOFA)
score, clinical situation assessment (presence or absence
of sepsis, severe sepsis, or septic shock), and Candida
score. Blood samples for the measurement of BDG,
CAGTA, mannan-Ag, and mannan-Ab were drawn at
the same time periods. In patients treated with empirical
or directed systemic antifungal treatment (SAT), clinical
and microbiological study controls were performed on
days 0, +3, +7, and +14 from the beginning of SAT. In
addition, blood cultures and samples for PCR detection
of Candida DNA were also obtained. Patients were
followed until ICU and/or hospital discharge, or death.
The indication of SAT was decided by the primary
clinician. Details of SAT including starting date, drug(s),
doses and duration of treatment were registered.
Definitions
Catheter-related candidemia was diagnosed in those pa-
tients who had an intravascular device and one or more
positive cultures of blood samples obtained from the
peripheral vein, clinical manifestations of infection (e.g.,
fever, chills, and/or hypertension), and no apparent
source for bloodstream infection (with the exception of
the catheter), as well as a positive catheter culture, either
semiquantitative culture (≥15 colony-forming units [cfu]
per catheter segment) or quantitative (≥1000 cfu per
catheter segment), whereby the same organism (species
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and susceptibility) were isolated from a catheter segment
and a peripheral blood sample. Candiduria was defined
in the presence of at least 104 cfu/mL of the same
Candida spp.
When BDG, CAGTA, mannan-Ag, and mannan-Ab
were assessed independently, positivity for IC required
values of any biomarker at or above the cutoff level in
two consecutive samples. Candida PCR (C-PCR) was
considered positive when Candida DNA was detected at
least in a single sample. When the combination of two
biomarkers was assessed, positivity for IC required
values of both biomarkers at or above the cutoff level in
a single sample, or values at or above the cutoff level for
at least one of these biomarkers in two consecutive
samples.
Candida colonization was considered unifocal when
Candida spp. was isolated from one site and multifocal
when Candida spp. was simultaneously isolated from vari-
ous noncontiguous sites, even if two different Candida spp.
were isolated. Low-grade Candida colonization was defined
when Candida spp. was isolated in one or more foci, in
one or two consecutive surveillance controls. High-grade
Candida spp. colonization was defined as colonization of at
least three body sites on two or more consecutive screening
days [14]. Invasive candidiasis or proven Candida infection
was defined as (i) primary candidemia (presence of
Candida spp. in one or more blood cultures obtained from
peripheral veins), and (ii) intra-abdominal candidiasis (IAC)
(on the basis of macroscopic findings and direct examin-
ation or positive culture for Candida spp. of the peritoneal
Fig. 1 Details of the study methodology
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fluid collected during operation or within 24 h from exter-
nal drainage) [15].
Patients were classified into the groups of neither colo-
nized nor infected, low-grade Candida spp. colonization,
high-grade Candida spp. colonization, and IC. In the
presence of candidemia, catheters were removed, and fun-
doscopy was performed.
Clinical, microbiological, and serological controls per-
formed during the diagnostic phase are shown in Fig. 1.
When the patient received systemic antifungal therapy
(SAT) (treatment phase), controls were performed at dif-
ferent time schedules and detection of Candida DNA by
PCR assay was included in the two first determinations.
Statistical analysis
Categorical variables are expressed as frequencies and
percentages, and continuous variables as mean and
standard deviation (SD) when data followed a normal
distribution, or as median and interquartile range (25th–
75th percentile) when distribution departed from nor-
mality. The percentages were compared using the chi-
square (χ2) test, the means by the F test, and the me-
dians by the Kruskal-Wallis test. Statistical significance
was set at P < 0.05. The performance of the BDG assay
was analyzed with ≥ 100 and ≥ 200 pg/mL cutoffs besides
the cutoff of ≥ 80 pg/mL. Sensitivity, specificity, and pre-
dictive values for the ability of each biomarker to dis-
criminate between the IC and the remaining groups
were calculated. Data were analyzed using the R pack-
age, version 3.1.0 (R Development Core Team, 2014)
[16].
Results
Study population and salient findings
The flow chart of the study population is shown in
Fig. 2. Of 322 eligible patients, 89 (27.6 %) were ex-
cluded for different reasons (Fig. 2). Data of 233 pa-
tients (67 % men, mean age 66.7 years) were
Fig. 2 Flow-chart of the study population
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Table 1 Details of surgical procedures
Operation Surgical procedures Total
1st 2nd 3rd
Surgery of the esophagus
Esophagectomy with/without gastrectomy 13 4 2 19
Surgery of the stomach
Gastric bypass (gastroduodenostomy, gastrojejunal, Roux-en-Y) 7 7 1 15
Radical subtotal gastrectomy 4 2 6
Total gastrectomy 4 1 1 6
Partial gastrectomy plus vagus nerve transection 2 2
Gastrorraphy 1 1
Gastrostomy 1 1
Surgery of the gallbladder, biliary tract, and liver
Cholecystectomy 26 1 27
Biliary tract surgery (cholecystostomy, bypasses, sphincteroplasty, etc.) 11 4 5 20
Segmental hepatectomy 6 6
Resection hydatid cyst 3 3
Open drainage of liver abscess 1 1 2
Resection hepatic tumor 1 1
Multiple or simple hepatorrhaphy 1 1
Surgery of the pancreas
Duodenocephalic pancreatectomy 11 2 13
Drainage pancreatic abscess 9 1 10
Distal, subtotal pancreatectomy or resection of pancreatic lesions 5 1 1 7
Surgery of the small intestine and colon
Intestinal resection: duodenectomy, enterocolectomy, enterectomy, jejunectomy 34 10 2 46
Subtotal colectomty (includes hemicolectomy and sigmoidectomy) 37 5 1 43
Colostomy or ileostomy (includes sigmoidostomy) duodenostomy 16 19 4 39
Intestinal anastomoses without resection (small intestine, small-large intestine, large intestine) 15 4 2 21
Total colectomy 7 7
Appendectomy 3 3
Closure of stoma 1 1 1 3
Drainage of diverticular abscess 2 2
Reduction of intestinal volvolus. Intestinal intussusception 2 2
Meckel’s diverticulum resection 1 1
Retroperitoneum
Drainage of intraperitoneal abscess (including epiploic, iliac fossa, perisplenic and perigastric) 5 12 17
Enterotomy: foreign body 2 2
Drainage retroperitoneal abscess 1 1 2
Other
Exploratory laparotomy 29 32 18 79
Drainage of abdominal wall abscess 2 2 2 6
Hernia repair with/without mesh 2 2 4
Splenectomy. Splenorrhaphy 1 1 2
Drainage subphrenic or subdiaphragmatic abscess 1 1 2
Resection lesion in the mesenterium or omentum 1 1
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analyzed. In relation to SAC, 211 patients underwent
426 operations (66 % on an emergency basis; 50 % related
to the colon, biliary tract, and pancreas; 37 % reopera-
tions) and 22 had acute pancreatitis. Details of surgical
procedures are shown in Table 1.
Thirty-one patients had IC (IAC 20; candidemia 11),
154 Candida spp. colonization (low-grade 130; high-
grade 24), and 48 were neither colonized nor infected.
The groups of IAC and high-grade colonization showed
significant differences as compared to the remaining
groups in Candida score, length of ICU stay, and num-
ber of surgical procedures; also, antifungal treatment
was significantly more frequent among patients with IC
(Table 2).
Data on risk factors, Candida colonization, CI, and
SAT are shown in Table 3. Twenty-three (74.1 %) of the
31 patients with IC had sepsis or septic shock, with a
median time between ICU admission and diagnosis of
infection of 7 days. The most common causative patho-
gens were C. albicans (51.6 %) and C. glabrata (22.6 %).
Of the 31 patients with IC, 29 (93.5 %) received SAT
(ICA 18, candidemia 11) and 2 died before indication of
antifungal therapy. The median time between ICU ad-
mission and beginning of SAT was similar for patients
with candidemia (6.5 days) and patients with IAC
(7 days). Empirical SAT was administered in 90 patients
(75.6 %), with severe sepsis or septic shock in 65, and a
median time between ICU admission and starting treat-
ment of 7 days. Patients treated with SAT for suspected
or documented Candida spp. infection showed similar
characteristics, except for a higher Candida score in
patients with IC (median [IQR] 4 [3, 4] vs. 4 [3–5],
P = 0.031).
Diagnostic value of BDG (cutoffs 80, 100 and 200 pg/mL),
CAGTA, mannan-Ag, mannan-Ab, and C-PCR alone
BDG, CAGTA, mannan-Ag, and mannan-Ab were mea-
sured in 860 samples (3.6 per patient), and C-PCR in
213, with positive results in 453, 306, 287, 150, and 110
samples, respectively. As shown in Tables 4 and 5, the
percentages of patients with positive BDG, CAGTA, and
mannan-Ag were significantly higher in the groups of
candidemia, IAC, and high-grade Candida spp.
colonization than in the remaining groups. When the
BDG assay was used with the different cutoffs, the
number of patients with positive results remained with-
out changes in the group with candidemia but decreased
in the groups of high-grade Candida spp. colonization
and IAC. Positivity of the BDG test (cutoff 80 pg/mL)
showed the highest sensitivity (76.7 %) and negative pre-
dictive value (94.1 %) as compared to other assays, al-
though CAGTA showed a higher specificity (64.3 %) and
a lower sensitivity (53.3 %) than BDG but the specificity
of BDG improved when increasing the cutoff from
80 pg/mL to 200 pg/mL. C-PCR had a sensitivity of
84 % and a specificity of 32.9 %. All 20 C-PCR healthy
controls were negative. The remaining tests showed a
much lower reliability for the diagnosis of IC.
Diagnostic value of combined use of BDG (cutoffs 80, 100
and 200 pg/mL), CAGTA, mannan-Ag, mannan-Ab, and
C-PCR
Positivity of the BDG test for the three thresholds (or
cutoffs) combined with positive results of the CAGTA,
mannan-Ag, and mannan-Ab tests, as well as positivity
of the CAGTA test combined with positive results of the
mannan-Ag and mannan-Ab tests were significantly
more frequent among patients with IAC, candidemia,
and high-grade Candida spp. colonization than among
those with low-grade Candida colonization and neither
colonized nor infected (Table 6). Similar results were ob-
tained for the combinations of positivities of C-PCR and
mannan-Ag as well as mannan-Ag and mannan-Ab,
which were also significantly more frequent among
patients with IC and high-grade colonization.
As shown in Table 6, in the group of candidemia, the
number of 10 patients with BDG and CAGTA positivi-
ties remained unchanged despite increasing the cutoff of
BDG from 80 pg/mL to 200 pg/mL. By contrast in the
group of IAC, the number of patients with BDG and
CAGTA positivities decreased from 18 at the cutoff of
80 pg/mL to 16 at 100 pg/mL and 14 at 200 pg/mL. In
the group of high-grade Candida spp. colonization, even
increasing the cutoff from 80 pg/mL to 200 pg/mL, 19
of the 24 patients continued to show positivities of both
BDG and CAGTA biomarkers. When the group of nei-
ther colonized nor infected or with low-grade Candida
spp. colonization was analyzed, the number of patients
with positive BDG and positive CAGTA decreased from
Table 1 Details of surgical procedures (Continued)
Aortobifemoral bypass 1 1
Endovascular repair of abdominal aortic aneurysm 1 1
Placement Bogota bag 1 1
Ileofemoral thromboendarterectomy 1 1
Total 426
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Table 2 Characteristics of the study population according to colonization and infection status
Diagnosis P value
Total NCI LGCC HGCC IAC Candidemia
(n = 233) (n = 48) (n = 130) (n = 24) (n = 20) (n = 11)
Age, years, mean (± SD) 66.7 ± 13.2 66.9 ± 11.9 65.8 ± 13.9 70.7 ± 9.2 67.1 ± 15.7 67.5 ± 12.2 .597
Male/female, % 67.0/33.0 72.9/27.1 70.0/30.0 50.0/50.0 60.0/40.0 54.5/45.5 .228
ICU admission
APACHE II 18.4 ± 6.3 18.1 ± 6.2 18.5 ± 6.1 18.2 ± 7.1 19.6 ± 7.0 18.3 ± 6.5 .925
SOFAa 7 (5 ; 9) 6.5 (5 ; 8) 7 (5 ; 10) 7.5 (4.5; 9.5) 6.5 (4 ; 10) 7.5 (5 ; 9) .583
Maximum score during ICU stay
APACHE II 18.7 ± 6.3 17.7 ± 6.6 18.3 ± 6.1 21.4 ± 7.7 19.4 ± 5.0 19.5 ± 4.7 .162
SOFAa 7 (5–10) 7 (4–9) 7 (5–10) 7 (5–10) 7 (5–12) 9 (5.5–10) .702
Candida scorea 4 (3–4) 3 (2–4) 4 (3–4) 4 (3–5) 4.5 (4–5) 3 (3–4) < .001
ICU length of stay, daysa 15 (10–25) 12 (8–19) 14 (9–25) 21 (17–28) 14 (11–19) 16 (8–38) .017
Hospital length of stay, daysa 37 (21–57) 34 (22–45) 33 (19–59) 48 (33–68) 37 (26–58) 40 (32–59) .097
Patient type, no. (%) .180
Medical 22 (9.4) 5 (10.4) 12 (9.2) 2 (8.3) 0 3 (27.3)
Surgical* 211 (90.6) 43 (89.6) 118 (90.8) 22 (91.7) 20 (100) 8 (72.7)
Pancreatitis not intervened 22 (9.4) 5 (10.4) 12 (9.2) 2 (8.3) 0 3 (27.3) .232
Site of abdominal surgery, no. (%) .701
Esophagus 13 (6.2) 4 (9.3) 5 (4.2) 2 (9.1) 2 (10.0) 0
Stomach/duodenum 21 (10.0) 1 (2.3) 14 (11.9) 3 (13.6) 3 (15.0) 0
Biliary tract/pancreas 58 (27.5) 9 (20.9) 38 (32.2) 5 (22.7) 3 (15.0) 3 (37.5)
Small intestine 45 (21.3) 13 (30.2) 21 (17.8) 4 (18.2) 5 (25.0) 2 (25.0)
Colon 59 (28.0) 12 (27.9) 32 (27.1) 6 (27.3) 6 (30.0) 3 (37.5)
Others 15 (7.1) 4 (9.3) 8 (6.8) 2 (9.1) 1 (5.0) 0
Surgery type**, no. (%)† .556
Emergency 135 (64.0) 24 (55.8) 78 (66.1) 13 (59.1) 15 (75.0) 5 (62.2)
Elective 76 (36.0) 19 (44.2) 40 (33.9) 9 (40.9) 5 (25.0) 3 (37.5)
Surgical procedure**, no. (%) .023
One 113 (53.6) 23 (53.5) 70 (59.3) 11 (50.0) 4 (20.0) 5 (62.5)
≥ Two 98 (46.4) 20 (46.5) 48 (40.7) 11 (50.0) 16 (80.0) 3 (37.5)
Underlying illnesses, no. (%)
Solid tumor 84 (36.1) 19 (39.6) 43 (33.1) 10 (41.7) 8 (40.0) 4 (36.4) .853
Diabetes mellitus 67 (28.8) 13 (27.1) 35 (26.9) 8 (33.3) 7 (35.0) 4 (36.4) .830
COPD 37 (15.9) 13 (27.1) 17 (13.1) 3 (12.5) 4 (20.0) 0 .112
Chronic renal failure 26 (11.2) 3 (6.2) 14 (10.8) 5 (20.8) 2 (10.0) 2 (18.2) .337
Heart failure 16 (6.9) 3 (6.2) 6 (4.6) 5 (20.8) 0 2 (18.2) .023
Chronic liver failure 9 (3.9) 4 (8.3) 3 (2.3) 2 (8.3) 0 0 .201
Oncohematologic process 3 (1.3) 0 2 (1.5) 1 (4.2) 0 0 .635
Antifungal treatment, no. (%) 119 (51.1) 21 (43.8) 58 (44.6) 11 (45.8) 18 (90.0) 11 (100) < .001
ICU mortality, no. (%) 50 (21.5) 8 (16.7) 30 (23.1) 7 (29.7) 4 (20.0) 1 (9.1) .605
Overall mortality, no. (%) 68 (29.2) 10 (20.8) 41 (31.5) 8 (33.3) 8 (40.0) 1 (9.1) .277
Values are expressed as frequencies and percentages; mean ± standard deviation (SD); amedian (25th-75th percentiles); P value: statistical significance
NCI neither colonized nor infected, LGCC low-grade Candida spp. colonization, HGCC high-grade Candida spp. colonization, IAC intra-abdominal candidiasis,
ICU intensive care unit, APACHE II Acute Physiology and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, COPD chronic obstructive
pulmonary disease
*Abdominal surgery; **211 patients, †first surgical procedure
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96 (53.9 %) for a cutoff of 80 pg/mL to 70 (39.3 %) for a
cutoff of 200 pg/mL.
The combination of BDG positivity with positive
values of other markers showed the highest sensitivities
(Table 7). BDG (cutoff 80 pg/mL) plus CAGTA showed
a sensitivity of 90.3 % and a negative predictive value of
96.6 %, although the specificity was only 42.1 %, increas-
ing to 55.9 % when the cutoff of BDG was 200 pg/mL.
The combination of BDG and mannan-Ag showed high
sensitivities and negative predictive values (80.6 % and
93.7 %, respectively), but a low specificity (44.1 %). C-PCR
showed the best specificities when combined with
mannan-Ag and mannan-Ab (63.5 % and 78.7 %, respect-
ively). The remaining combinations were less relevant.
In the association of positive BDG and positive
CAGTA, which was the combination with the highest
diagnostic performance, the sensitivity decreased and
the specific increased as the cutoffs changed from
80 pg/mL to 100 pg/mL and to 200 pg/mL.
Discussion
Because of difficulties in the diagnosis IC in ICU set-
tings, up to two thirds of critically ill patients with suspi-
cion of fungal infection are given empirical antifungals
[17, 18], a strategy with a well-recognized negative im-
pact on adverse effects, risk of resistances [5], length of
stay, patient’s outcome, and health care costs [19, 20]. In
the present series, 51 % of patients received SAT and
Table 3 Risk factors, Candida colonization (low and high grade)
and infection, and antifungal therapy characteristics of patients
Included patients n = 185*
Risk factors, no. (%)
Broad-spectrum antibiotics 184 (99.5)
Urinary catheter 183 (98.9)
Central venous catheter 183 (98.9)
Arterial catheter 165 (89.2)
Mechanical ventilation 156 (84.3)
Parenteral nutrition 155 (83.8)
Corticosteroids 73 (39.5)
Renal replacement therapy 54 (29.2)
Candida colonization (n = 154)
Low-grade Candida spp. colonization, no. (%) 130 (84.4)
High-grade Candida spp. colonization, no. (%) 24 (15.6)
Candida score≥ 3; first week/during study 96/142 (51.9)
Candida infection (n = 31)
Severity of Candida infection at diagnosis
No sepsis/sepsis 3/5
Severe sepsis/septic shock 9/14
Causative Candida spp
C. albicans 16 (51.6)
C. glabrata 7 (22.6)
C. parapsilosis 3 (9.7)
C. tropicalis 1 3.2)
C. krusei 1 (3.2)
C. dubliniensis 1 (3.2)
C. famata 1 (3.2)
C. albicans + C. glabrata 1 (3.2)
Time between hospital admission to infection, daysa 16 (6.5–19.5)
Time between ICU admission to infection, daysa 7 (2–13)
Hospital/ICU mortality, no. (%) 9 (29.0/5 (16.1)
Systemic antifungal therapy (SAT) (n = 119)**
Empirical therapy for suspected IC (n = 90)***
Multifocal colonization, no. (%) 50 (55.6)
Clinical situation, no. (%)
No sepsis/sepsis 8 (8.9)/17 (18.9)
Severe sepsis/septic shock 29 (32.2)/36 (40.0)
APACHE II 17.8 ± 6.2
SOFAa 6 (5–9)
Candida score 4 (3–4)
Time between of hospital/and beginning of SAT,
daysa
11 (7–19)
Time between ICU admission and beginning of SAT,
daysa
7 (1–11)
Hospital/ICU mortality, no. (%) 29 (32.2)/23 (25.6)
Table 3 Risk factors, Candida colonization (low and high grade)
and infection, and antifungal therapy characteristics of patients
(Continued)
Therapy for documented infection (n = 29)***
Clinical situation
No sepsis/sepsis 3 (10.3)/4 (13.8)
Severe sepsis/septic shock 8 (27.6)/14 (48.3)
APACHE II 18.8 ± 6.8
SOFAa 6.5 (4–10)
Candida score 4 (3–5)
Time between of hospital/ICU admission and
beginning of SAT, daysa
Candidemia (11) 15 (4.5 ; 22)/6.5 (1 ;
16)
Intra-abdominal candidiasis (18) 12.5 (8 ; 17)/7 (3 ; 12)
Antifungal agents (>1 agent/patient)
Days of therapy (first SAT)a 15 (8–21)
Values are expressed as frequencies and percentages; mean ± standard
deviation (SD); amedian (interquartile range, 25th–75th percentile)
ICU intensive care unit, SAT systemic antifungal therapy, IC invasive candidiasis,
APACHE II Acute Physiology and Chronic Health Evaluation, SOFA Sequential
Organ Failure Assessment
*Patients with Candida colonization (low and high grade) (n = 154) plus invasive
candidiasis (n = 31), **patients with Candida colonization (n = 90) and IC (n = 29);
***starting antifungal therapy
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75.6 % of them did not have documented IC. Therefore,
the availability of accurate tests to support either the ini-
tiation or discontinuation of SAT is a decision of crucial
importance. The clinician can prescribe SAT if two con-
secutive [21–26] or more positive BDG determinations
within 48 hours are present, or may stop SAT when
BDG and CAGTA are negative in a single sample due to
the high negative predictive value of this combination.
Also, performance of BDG as a complementary test to
blood cultures is currently under the scope of various
clinical recommendations [27–29]. Bailly et al. [30] have
recently demonstrated that in the absence of proven IC
empiric SAT treatment could be safely stopped after
5 days of therapy without apparent deleterious effect on
day-28 mortality.
According to the present findings, positive BDG and
positive CAGTA levels in a single sample or at least
positivity of one of the two biomarkers in two consecu-
tive samples was the best way of characterizing IC
diagnosis in non-neutropenic ICU patients with SAC. By
contrast, individual or combined positivities of C-PCR,
mannan-Ag, and mannan-Ab were of little value for dis-
criminating IC from Candida spp. colonization. These
results are relevant in daily practice for making decisions
in complex clinical care settings.
Different studies have assessed the clinical value of
CAGTA. The group of Martinez-Jiménez et al. [31]
showed that the presence of a positive CAGTA test in a
sample from a patient with candidemia suggests deep-
seated candidiasis, and more recently, provided evidence
that the combination of CAGTA and BDG, or CAGTA
and mannan-Ag, had high negative predictive values
[32]. In 63 ICU patients and 37 non-ICU patients
treated with antifungals, these authors achieved a sensi-
tivity of 96.7 % and negative predictive value of 97.1 %
when the combination (BDG and CAGTA at 1/60 cut-
off ) was positive on days 0, +3, and +5 after starting
antifungal therapy. In this study, serial determination of
Table 4 Number of patients with BDG (cutoff 80, 100 and 200 pg/mL), CAGTA, MANNAN biomarkers and Candida PCR positives
used alone in the five study groups
Candida spp colonization
NCI LGCC HGCC IAC Candidemia P
N = 48 N = 130 N = 24 N = 20 N = 11
BDG≥ 80 pg/mL, no. (%) 16/46 (34.8)a 50/124 (40.3)a 17/24 (70.8)b 15/20 (75.0)b 8/10 (80.0)b < .001
BDG≥ 100 pg/mL, no. (%) 16/46 (34.8)a 45/125 (36.0)a 14/24 (58.3)a,b 13/20 (65.0)b 8/10 (80.0) b .004
BDG≥ 200 pg/mL, no. (%) 10/47 (21.3)a 20/128 (15.6)a 11/24 (45.8)b 10/20 (50.0)b 8/10 (80.0)b < .001
CAGTA positive, no. (%) 10/47 (21.3)a 44/128 (34.4)a 17/24 (70.8)b 8/20 (40.0)a,b 8/10 (80.0)b < .001
Mannan-Ag positive, no. (%) 10/48 (20.8)a 40/127 (31.5)a 15/24 (62.5)b 8/20 (40.0)a,b 5/10 (50.0)a,b .007
Mannan-Ab positive, no. (%) 6/48 (12.5) 12/128 (9.4) 4/24 (16.7) 5/20 (25.0) 3/11 (27.3) .126
C-PCR positive, no. (%) 14/23 (60.9) 37/54 (68.5) 6/8 (75.0) 12/14 (85.7) 9/11(81.8) .525
Values are frequencies and percentages. Different superscripts (a,b) indicate nominally significant differences (P < 0.05). Biomarker positives: two determinations
consecutives positives (≥ cutoff). C-PCR positive: one determination positive
NCI neither colonized nor infected, LGCC low-grade Candida spp. colonization, HGCC high-grade Candida spp. colonization, IAC intra-abdominal candidiasis, BDG
(1-3)-ß-D-glucan, CAGTA Candida albicans germ tube antibody, mannan-Ag mannan antigen, mannan-Ab mannan antibody, C-PCR PCR-based Candida detection
Table 5 Performances of BDG (cutoff 80, 100 and 200 pg/mL), CAGTA, MANNAN biomarkers and C-PCR used alone for IC diagnosis
Invasive candidiasis Sensitivity % Specificity % NPV % PPV %
(95 % CI) (95 % CI) (95 % CI) (95 % CI)
BDG≥ 80 pg/mL 76.7 (57.7–90.1) 57.2 (49.9–64.3) 94.1 (89.1–96.8) 21.7 (17.7–26.4)
BDG≥ 100 pg/mL 70.0 (50.6–85.3) 61.5 (54.3–68.4) 93.0 (88.4–95.9) 21.9 (17.3–27.3)
BDG≥ 200 pg/mL 60.0 (40.6–77.3) 79.4 (73.1–84.8) 92.9 (89.4–95.4) 30.5 (22.7–39.6)
CAGTA positive 53.3 (34.3–71.7) 64.3 (57.2–71.0) 90.1 (86.0–93.2) 18.4 (13.3–24.8)
Mannan-Ag positive 43.3 (25.5–62.6) 67.3 (60.3–73.8) 88.7 (85.0–91.6) 16.7 (11.3–24.0)
Mannan-Ab positive 25.8 (11.9–44.6) 89.0 (83.8–93.0) 88.6 (86.2–90.6) 26.7 (15.1– 42.6)
C-PCR positive 84.0 (63.9–95.5) 32.9 (23.1–44.0) 87.5 (73.1–94.8) 26.9 (22.7–31.6)
Values are frequencies and percentages. Biomarker positives: two determinations consecutives positives (≥ cutoff). C-PCR positive: one determination positive
NCI neither colonized nor infected, LGCC low-grade Candida spp. colonization, HGCC high-grade Candida spp. colonization, IAC intra-abdominal candidiasis, BDG
(1-3)-ß-D-glucan, CAGTA Candida albicans germ tube antibody, mannan-Ag mannan antigen; mannan-Ab mannan antibody, C-PCR PCR-based Candida detection
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BDG and CAGTA could be used to stop safely antifun-
gals in 31 % of patients receiving empirical antifungal
therapy both in ICU and non-ICU wards [33].
The advantage of combining BDG and CAGTA for ac-
curate diagnosis of IC is consistent with our findings in
selected ICU patients with SAC, with a sensitivity of
90.3 % and a negative predictive value of 96.6 %. Al-
though the specificity was only 42.1 %, the combination
of BDG and CAGTA was positive in 21 of 24 patients
with high-grade Candida spp. colonization, which prob-
ably indicates a hidden IC or a high probability of devel-
oping candidemia, two circumstances in which starting
empirical antifungals would be justified. Also, the high
negative predictive value could be useful for excluding
Candida spp. infection in patients receiving empirical
SAT.
The combination of mannan-Ag and mannan-Ab has
been also recommended [28, 34] but results of clinical
studies are not very encouraging, with a diagnostic spe-
cificity of 51 % and sensitivity of 77 % in a retrospective
analysis of 162 patients of whom 91 had proven IC [35].
In samples from 31 patients with candidemia and 50
patients with bacteremia, the use of mannan-Ag and
mannan-Ab alone showed sensitivities of 64.3 % and
61.5 %, specificities of 95.7 % and 65.8 %, and negative
predictive values of 81.8 % and 71.4 %, respectively [32].
In our study, positive mannan-Ag tests were more fre-
quent in patients with high-grade Candida colonization
(65.5 %) and candidemia (50 %), whereas the rate of
positive mannan-Ab tests was low in all study groups.
However, both tests had a low sensitivity for diagnosing
IC possibly in relation to the limited capacity to produce
specific antibodies in the presence of immunosuppres-
sion [9, 33].
Currently, molecular techniques are increasingly used
to diagnose invasive fungal infections [8, 9]. Results of a
meta-analysis with 54 studies and 4694 patients, PCR
positivity rates among patients with proven or prob-
able IC were 85 %, while blood cultures were positive
for 38 % [36]. In 63 ICU patients with suspected IC
(eventually confirmed in 27) and 40 healthy controls,
the sensitivity, specificity, positive predictive value and
negative predictive value of MRT-PCR for the diagnosis of
IC were 96.3 %, 97.3 %, 92.8 % and 98.7 %, respectively.
Table 6 Number of patients with BDG (cutoff 80, 100 and 200 pg/mL) CAGTA, MANNAN biomarkers and Candida PCR positives
used combined in the five study groups
Candida spp. colonization
NCI LGCC HGCC IAC Candidemia P
N = 48 N = 130 N = 24 N = 20 N = 11
BDG ≥80 pg/mL CAGTA 21 (43.8)a 75 (57.7)a 21 (87.5)b 18 (90.0)b 10 (90.9)b < .001
Mannan-Ag 21 (43.8)a 71 (54.6)a,c 21 (87.5)b 16 (80.0)b 9 (81.8)b,c <.001
Mannan-Ab 21 (43.8)a 61 (46.9)a 19 (79.2)b,c 15 (75.0)c 8 (72.7)a,c .002
C-PCR 14/23 (60.9) 32/54 (59.3) 5/8 (62.5) 11/14 (78.6) 8/11 (72.7) .724
BDG ≥100 pg/mL CAGTA 21 (43.8)a 72 (55.4)a 20 (83.3)b 16 (80.0)b 10 (90.9)b < .001
Mannan-Ag 21 (43.8)a 68 (52.3)a, c 19 (79.2)b 14 (70.0)a, b, c 9 (81.8)c .009
Mannan-Ab 21 (43.8) 57 (43.8) 16 (66.7) 13 (65.0) 8 (72.7) .053
C-PCR 14/23 (60.9) 28/54 (51.9) 5/8 (62.5) 10/14 (71.4) 8/11 (72.7) .606
BDG ≥200 pg/mL CAGTA 16 (33.3)a 54 (41.5)a 19 (79.2)b 14 (70.0)b 10 (90.9)b < .001
Mannan-Ag 15 (31.2)a 52 (40.0)a 18 (75.0)b 13 (65.0)b 9 (81.8)b < .001
Mannan-Ab 13 (27.1)a 33 (25.4)a 13 (54.2)b 12 (60.0)b 8 (72.7)b < .001
C-PCR 10/23 (43.5) 21/54 (38.9) 3/8 (37.5) 10/14 (71.4) 8/11 (72.7) .089
CAGTA positive Mannan-Ag 15 (31.2)a 63 (48.5)b 21 (87.5)c 11 (55.0)a,b 10 (90.9)c < .001
Mannan-Ab 14 (29.2)a 53 (40.8)a,c 18 (75.0)b 12 (60.0)b,c 8 (72.7)b < .001
C-PCR 8/23 (34.8) 25/54 (46.3) 5/8 (62.5) 6/14 (42.9) 8/11 (72.7) .278
C-PCR positive Mannan-Ag 5/23 (21.7)a 21/54 (38.9)a 5/8 (62.5)a,b 7/14 (50.0)a 8/11 (72.7)b .037
Mannan-Ab 8/23 (34.8) 19/54 (35.2) 1/8 (12.5) 7/14 (50.0) 8/11 (72.7) .073
Mannan-Ag positive Mannan-Ab 13 (27.1)a 51 (39.2)a,b 17 (70.8)c 12 (60.0)b,c 5 (45.5)a,c .003
Values are frequencies and percentages. Combined biomarkers and C-PCR: two consecutive determinations positives or/and at least one of each biomarkers
(in one determination) positive. C-PCR: one determination positive
NCI neither colonized nor infected, LGCC low-grade Candida spp. colonization, HGCC high-grade Candida spp. colonization, IAC intra-abdominal candidiasis, BDG
(1-3)-ß-D-glucan, CAGTA Candida albicans germ tube antibody, mannan-Ag mannan antigen, mannan-Ab mannan antibody, C-PCR PCR-based Candida detection
Different superscripts (a,b,c) indicate nominally significant differences (P < .05)
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Also, in deep-seated IC, the sensitivity of PCR was
90.9 % vs. 45.4 % for blood cultures (P = 0.06) [13]. In
our study, positive PCR tests were more frequent in
patients with IC and high-grade Candida colonization,
although the diagnostic accuracy was low. However, wide
standardization of molecular tests has not been reached
and results should be considered with caution.
Other studies have examined the combinations of bio-
markers with inconsistent results. Nguyen et al. [37] in
blood samples collected prospectively from 55 patients
with IC and 73 controls, PCR and BDG were similar for
diagnosing candidemia (59 % vs. 68 %) but PCR was
more sensitive for deep-seated candidiasis (89 % vs.
53 %; P = 0.004), and both (PCR and BDG) were more
sensitive than blood cultures among patients with deep-
seated candidiasis. Held et al. [38] evaluated the useful-
ness of BDG, mannan-Ag with/without mannan-Ab, and
Cand-Tec Candida antigen in a case-control study. The
combination of BDG and mannan-Ag was superior to the
other combinations with 89.3 % sensitivity and 85.0 % spe-
cificity. In a previous study of our group in ICU patients
with SAC [20], BDG levels > 259 pg/mL combined with
CAGTA positive results accurately discriminated Candida
spp. colonization from IC (sensitivity 90.3 %, specificity
54.8 %, and negative predictive value 93.9 %).
This study has also its limitations. First, the number of
IC was small and this is important because we think that
BDG and CAGTA behave differently in candidemia and
in deep-seated candidiasis, such as IAC. The number of
patients was not sufficient for a reliable analysis of the
differences in biomarkers accuracy between IAC and
candidemia. Second, although we applied strict criteria
for the diagnose IAC, Candida spp. isolation in periton-
eal exudates is difficult and the role of unregistered poly-
microbial cultures is hard to establish. Third, the BDG
and PCR tests were performed in frozen samples, so that
false negative results are possible due to instability of the
samples. Fourth, the presence of intestinal mucositis
may facilitate the translocation of Candida spp. through
the gastrointestinal barrier and eventually may inter-
fere with BDG measurements. Finally, we should take
into account the potential impact of echinocandins on
BDG synthesis because, in the current study, 119 pa-
tients, approximately half of the studied patients, re-
ceived SAT and nearly 60 % of them were treated with
echinocandins.
Our study demonstrates that BDG, in contrast to other
methods, is the best biomarker to be used in the diagnosis
of IC in the critically ill patient with SAC. When BDG is
used in combination with CAGTA, its diagnostic
Table 7 Performances of BDG (cutoff 80, 100 and 200 pg/mL), CAGTA, MANNAN biomarkers and C-PCR used combined for IC
diagnosis
Invasive candidiasis Sensitivity % Specificity % NPV % PPV %
(95 % CI) (95 % CI) (95 % CI) (95 % CI)
BDG ≥80 pg/mL CAGTA 90.3 (74.2–98.0) 42.1 (35.2–49.2) 96.6 (90.5–98.8) 19.3 (16.9–22.0)
Mannan-Ag 80.6 (62.5–92.5) 44.1 (37.1–51.2) 93.7 (87.7–96.9) 18.1 (15.2–21.5)
Mannan-Ab 74.2 (42.9–57.1) 50.0 (42.9–57.1) 92.7 (87.2–95.9) 18.5 (15.1–22.6)
C-PCR 76.0 (54.9–90.6) 40.0 (29.5–51.2) 85.0 (72.9–92.3) 27.1 (22.0–33.0)
BDG ≥100 pg/mL CAGTA 83.9 (66.3–94.5) 44.1 (37.1–51.2) 94.7 (88.7–97.6) 18.7 (15.9–21.9)
Mannan-Ag 74.2 (55.4–88.1) 46.5 (39.5–53.7) 92.2 (86.4–95.6) 17.6 (14.3–21.4)
Mannan-Ab 67.7 (48.6–83.3) 53.5 (46.3–60.5) 91.5 (86.5–94.8) 18.3 (14.4–22.9)
C-PCR 72.0 (50.6–87.9) 44.7 (33.9–55.9) 84.4 (73.5–91.4) 27.7 (21.9–34.3)
BDG ≥200 pg/mL CAGTA 77.4 (58.9–96.9) 55.9 (48.8–62.9) 94.2 (89.3–96.9) 21.2 (17.4–25.6)
Mannan-Ag 71.0 (52.0–85.8) 57.9 (50.8–64.8) 92.9 (88.1–95.8) 20.6 (16.4–25.5)
Mannan-Ab 64.5 (45.4–80.8) 70.8 (64.0–77.0) 92.9 (88.9–95.5) 25.3 (19.5–32.2)
C-PCR 72.0 (50.6–87.9) 60.0 (48.8–70.5) 87.9 (79.1–93.3) 34.6 (27.0–43.1)
CAGTA positive Mannan-Ag 67.7 (48.6–83.3) 51.0 (43.9–58.1) 91.2 (85.9–94.6) 17.5 (13.8–21.9)
Mannan-Ab 64.5 (45.4–80.8) 57.9 (50.8–64.8) 91.4 (86.7–94.5) 19.0 (14.8–24.2)
C-PCR 56.0 (34.9–75.6) 55.3 (44.1–66.1) 81.0 (72.5–87.4) 26.9 (19.5–35.9)
C-PCR positive Mannan-Ag 60.0 (38.7–78.9) 63.5 (52.4–73.7) 84.4 (76.5–90.0) 32.6 (24.0–42.5)
Mannan-Ab 54.8 (36.0–72.7) 78.7 (72.4–84.1) 91.9 (88.4–94.4) 28.3 (20.7–37.5)
Mannan-Ag positive Mannan-Ab 54.8 (36.0–72.7) 59.9 (52.8–66.7) 89.6 (85.2–92.8) 17.3 (12.8–23.1)
Combined biomarkers and C-PCR: two consecutive determinations positive or/and at least one of the biomarkers (in one determination) positive. C-PCR: one
determination positive
BDG (1-3)-ß-D-glucan, CAGTA Candida albicans germ tube antibody, mannan-Ag mannan antigen, mannan-Ab mannan antibody, C-PCR PCR-based Candida detection
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performance increases notably. The stratification of colo-
nized patients (in high-grade and low-grade) and of IC (in
candidemia and IAC) allowed us to observe that behavior
of these biomarkers is different in these clinical scenarios,
particularly when BDG with different cutoffs is used. The
association of BDG and CAGTA positivities is an excellent
diagnostic tool for candidemia, independently of the cutoff
value of BDG, but this was not the case for IAC where the
number of patients with BDG and CAGTA positivities de-
creases as the cutoff value of BDG increases. In cases of
high-grade Candida spp. colonization, the percentage of
patients with both BDG and CAGTA positive results de-
creases slightly (two patients) when the BDG cutoff in-
creases, which can raise the possibility of a very likely
presence of “occult” IC (especially candidemia). From a
practical clinical point of view, it may be stated that in
critically ill patients with SAC and BDG/CAGTA positiv-
ity, with a cutoff of BDG of ≥ 80 pg/mL, the need to start
antifungal treatment should be considered, covering the
three aforementioned possible clinical scenarios. Another
practical issue of combined BDG and CAGTA positivity is
the high negative predictive value (96.6 %), which would
raise the possibility of stopping an empirical antifungal
therapy. However, in patients without Candida
colonization or with low-grade Candida spp. colonization,
the association of BDG and CAGTA is positive in 53.9 %
of patients, which logically decreases to 39.3 % when a
BDG cutoff of 200 pg/mL is used.
Conclusions
In selected, non-neutropenic critically ill patients with
SAC, the combination of BDG and CAGTA positivities
in a single determination or at least one of the two bio-
markers positive in two consecutive samples, allowed
discriminating between IC and the groups of low-grade
and high-grade Candida colonization as well as neither
colonized nor infected. Other tests including PCR
Candida DNA detection and serum levels of mannan-
Ag and mannan-Ab alone or combined did not improve
the diagnostic yield. These clinically relevant findings
can be exploited to tailor empirical systemic antifungal
therapy in ICU patients with SAC.
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